This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Duke University, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2017-2018.
Company Filing History:
2 out of 2,075 
2 out of 3,690 
Years Active: 2017-2018
Title: The Innovative Contributions of Patrick C. Gedeon
Introduction
Patrick C. Gedeon is a notable inventor based in Durham, NC, who has made significant strides in the field of biotechnology. He holds two patents that focus on bispecific antibody engaging molecules, which have the potential to revolutionize cancer treatment. His work emphasizes the importance of targeted therapies in modern medicine.
Latest Patents
Gedeon's latest patents include "Human bispecific EGFRvIII and CD3 antibody engaging molecules" and "Human bispecific EGFRvIII antibody and CD3 engaging molecules." The first patent describes a polynucleotide encoding a bispecific antibody engaging molecule designed to target tumor cells expressing the human EGFRvIII mutant protein. This molecule also engages T cell activation ligand CD3, enhancing the immune response against cancer cells. The polynucleotide is optimized for expression in CHO cells, ensuring efficient production. The second patent outlines similar engaging molecules that are highly cytotoxic and antigen-specific, further establishing their potential as therapeutic agents.
Career Highlights
Throughout his career, Patrick C. Gedeon has worked with prestigious institutions such as Duke University and the National Institutes of Health, a component of the US Department of Health & Human Services. His contributions to the field of biotechnology have been recognized for their innovative approach to cancer treatment.
Collaborations
Gedeon has collaborated with esteemed colleagues, including Darell D. Bigner and John Howard Sampson, who have also made significant contributions to cancer research. Their combined expertise has fostered advancements in therapeutic strategies.
Conclusion
Patrick C. Gedeon's work in developing bispecific antibody engaging molecules showcases his commitment to advancing cancer therapies. His innovative patents and collaborations highlight the potential for targeted treatments in improving patient outcomes.